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Abstract
Introduction: Humans are widely exposed to estrogenically active phthalates, parabens, and phenols, raising
concerns about potential effects on breast tissue and breast cancer risk. We sought to determine the association of
circulating serum levels of these chemicals (reflecting recent exposure) with mammographic breast density
(a marker of breast cancer risk).
Methods: We recruited postmenopausal women aged 55 to 70 years from mammography clinics in Madison,
Wisconsin (N = 264). Subjects completed a questionnaire and provided a blood sample that was analyzed for
mono-ethyl phthalate, mono-butyl phthalate, mono-benzyl phthalate, butyl paraben, propyl paraben, octylphenol,
nonylphenol, and bisphenol A (BPA). Percentage breast density was measured from mammograms by using a
computer-assisted thresholding method.
Results: Serum BPA was positively associated with mammographic breast density after adjusting for age, body
mass index, and other potentially confounding factors. Mean percentage density was 12.6% (95% confidence
interval (CI), 11.4 to 14.0) among the 193 women with nondetectable BPA levels, 13.7% (95% CI, 10.7 to 17.1)
among the 35 women with detectable levels below the median (<0.55 ng/ml), and 17.6% (95% CI, 14.1 to 21.5)
among the 34 women with detectable levels above the median (>0.55 ng/ml; Ptrend = 0.01). Percentage breast
density was also elevated (18.2%; 95% CI, 13.4 to 23.7) among the 18 women with serum mono-ethyl phthalate
above the median detected level (>3.77 ng/ml) compared with women with nondetectable BPA levels (13.1%; 95%
CI, 11.9 to 14.3; Ptrend = 0.07). No other chemicals demonstrated associations with percentage breast density.
Conclusions: Postmenopausal women with high serum levels of BPA and mono-ethyl phthalate had elevated
breast density. Further investigation of the impact of BPA and mono-ethyl phthalate on breast cancer risk by using
repeated serum measurements or other markers of xenoestrogen exposure are needed.
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Introduction
Humans are widely exposed to estrogenically active envir-
onmental chemicals ("xenoestrogens”) in the course of
everyday life. Phthalates, parabens, and phenols are three
of the most common classes of xenoestrogens found in
foods and consumer products. Phthalates are used as a
plasticizer in many consumer plastics, adhesives, deter-
gents, and pharmaceuticals, and are also found in personal
care products, such as shampoos, lotions, and shaving
products [1]. Parabens are used as a preservative in many
of the same personal care products and pharmaceuticals,
and are additionally used as antimicrobials in foods [2].
Phenols are commonly used in the manufacture of consu-
mer products made of polycarbonate plastics, the coatings
of food containers, and as surfactants in detergents and
personal care products [3]. Data from the National Health
and Nutrition Examination Survey (NHANES) show that
the most common phthalates, parabens, and phenols are
detectable in the urine of more than 90% of Americans
[4-6].
Health concerns regarding exposure to xenoestrogens
stem from their potential actions as endocrine disruptors.
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Laboratory studies have demonstrated that many phtha-
lates, parabens, and phenols can bind to and activate the
estrogen receptor, promote the proliferation of human
breast cancer cells, or increase uterine weight in imma-
ture mice [2,7-9]. Many of these chemicals have the abil-
ity to induce additional biologic effects, including DNA
damage, altered DNA methylation, and altered sex hor-
mone metabolism [10-13].
Investigation of the health effects of these chemicals in
humans is limited by challenges in exposure assessment
because of their rapid metabolism. Measurements of
phthalates, parabens, and phenols in urine and serum
primarily reflect exposures within the past 24 hours
[1-3], which may not be correlated with long-term expo-
sure. However, a handful of studies have reported asso-
ciations with various health outcomes. Elevated serum
bisphenol A (BPA) levels were associated with recurrent
miscarriage in a small case-control study [14], and ele-
vated urinary BPA levels were associated with cardiovas-
cular disease in NHANES [15]. A variety of studies have
reported links between urinary or serum phthalate levels
and impaired sperm function in men [16], endometriosis
in women [17], early puberty [18], and premature breast
development [19]. Most recently, a case-control study of
women in Northern Mexico found that urinary levels of
mono-ethyl phthalate were positively associated with
breast cancer risk [20]. These findings raise important
questions regarding the potential impacts of phthalates
and other similar chemicals on breast tissue.
Mammographic breast density is one of the strongest
risk factors for breast cancer, and a useful marker for
the effects of various exposures on breast tissue [21].
Mammographic breast density refers to the appearance of
breast tissue on a mammogram, reflecting the relative
amounts of radiodense epithelial and stromal tissue versus
radiolucent fat tissue; breast density is qualitatively rated
by radiologists from mammograms on a routine basis but
may also be measured quantitatively for research through
various techniques [21]. A meta-analysis has estimated
that women with mammographically dense tissue in 75%
or more of the total breast area have a 4.2-fold increase in
breast cancer risk compared with women with less than
5% mammographic breast density [22]. Numerous breast
cancer risk factors have been associated with mammo-
graphic breast density [21], and mammographic breast
density responds to changes in exposures, including post-
menopausal hormone use [23,24] and chemoprevention
with tamoxifen [25].
We hypothesized that circulating serum levels of phtha-
lates, parabens, and phenols may be positively associated
with mammographic breast density. We examined this
relation in the Wisconsin Breast Density Study, a cross-




The Wisconsin Breast Density Study is a cross-sectional
study of women receiving screening mammograms at the
UW Health West Clinic or UW Health Breast Center in
Madison, Wisconsin [26,27]. The study was approved by
the University of Wisconsin Health Sciences Institutional
Review Board, and all subjects provide written informed
consent. Details on subject recruitment were previously
described [27]. In brief, eligibility was limited to postme-
nopausal women between the ages of 55 and 70 years who
attended the mammography clinics for a screening mam-
mogram between June 2008 and June 2009. Eligibility was
further limited to women with no history of postmenopau-
sal hormone use, breast implants, or a previous diagnosis
of breast cancer. In total, 268 subjects were enrolled in the
study.
Data collection
Each subject completed a study questionnaire and pro-
vided a blood sample immediately after completion of the
screening mammogram. The questionnaire assessed estab-
lished breast cancer risk factors and known correlates of
mammographic breast density, including demographic
and anthropometric factors, reproductive and menstrual
history, family history of breast cancer, and lifestyle factors
such as alcohol consumption, smoking, and physical
activity.
A 30-ml blood sample was collected from each subject
by venipuncture into uncoated glass vacutainer tubes
(Fisher Scientific, Pittsburgh, PA, USA). Immediately
after spinning down of the sample, 4.5 ml of serum was
transferred into borosilicate glass vials (Wheaton Science
Products, Millville, NJ, USA). The glass vials were pre-
pared by baking at 450°C to burn off all organic carbon,
and the Teflon-coated caps were sonicated in methanol
to remove any contaminants. The caps and vials were
then assembled in a biosafety cabinet and remained
sealed until the serum sample was collected. The serum
samples were stored frozen in the glass vials at -70°C
until thawed for analysis.
Free concentrations of phthalates, parabens, and phe-
nols were quantified at the Wisconsin State Laboratory
of Hygiene by using methods based on solid-phase
extraction (Strata-X; Phemomenex, Torrance, CA, USA)
and isotope dilution high-performance liquid chromato-
graphy (Agilent 1100, Waldbronn, Germany) with tandem
mass spectrometry (API4000; AB/SCIEX, Framingham,
MA, USA) with APCI negative ionization [28,29]. Analyti-
cal quality assurance (QA) parameters included reagent
(all <LOD) and method blanks (all <LOD with exception
of nonylphenol, for which five of nine were >LOD), cali-
bration check standards (recovery = 98.7% to 114.1%; n =
31 for phthalates and parabens and n = 20 for phenols),
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and double charcoal-treated human serum matrix control
spikes at low (1 ng/ml; recovery = 82.9% to 114%; n = 12
for phthalates and parabens and n = 14 for phenols) and
mid (5 and 10 ng/ml; recovery = 87.4% to 112.9%; n = 12
for phthalates and parabens and n = 19 for phenols) cali-
bration-curve levels. Lower limits of detection were based
on observed 3:1 signal-to-noise ratios, and are listed in
Table 2.
As previously described [27], endogenous estradiol was
measured at the Reproductive Endocrine Research
Laboratory at the University of Southern California by
using validated radioimmunoassays.
Mammographic breast density was quantitatively
assessed as previously described [26,27]. All subjects
received a screening mammogram on a digital machine.
Full-resolution digital images of the craniocaudal view of
the left breast were analyzed for breast density by using a
computer-assisted thresholding technique implemented
by Cumulus software [30]. Total breast area and dense
area were recorded by a single trained operator (EJAB)
with high reliability (intraclass correlation coefficients
>0.92 for repeated measures). Percentage breast density
was calculated as the ratio of dense to total breast area.
All enrolled subjects were included in the study, regard-
less of the clinical assessment of their mammograms.
Statistical analysis
All statistical analyses were performed by using SAS Sta-
tistical Software (Version 9.2; SAS Institute, Inc., Cary,
NC, USA). Insufficient serum was available for four study
subjects, leaving a total of 264 samples for analysis.
Serum propyl paraben level was missing for one woman,
serum octylphenol was missing for one woman, body
mass index was missing for two women, and education
level was missing for one woman. Multiple imputation
was used for missing covariate data, with 10 imputations
using the Markov Chain Monte Carlo method [31]. The
imputation model contained percentage breast density
and all variables listed in Tables 1 and 2. For statistical
analyses, each model was fit separately to the 10 imputed
datasets, and the results combined for statistical infer-
ences by using the methods of Rubin [32].
Percentage breast density was square-root transformed
to improve the normality of the data. Multivariable linear
regression was used to assess the association between
each xenoestrogen blood measure and the square root of
percentage breast density, while adjusting for age, body
mass index (BMI), and other variables that previously
were shown to be associated with density in this study
population: parity, family history of breast cancer, vigor-
ous physical activity, and pack-years of smoking [27].
Visual inspection of the data revealed two outlier values
of mono-ethyl phthalate (92 ng/ml and 130 ng/ml)
and two outlier values of bisphenol A (10.7 ng/ml and
14.5 ng/ml), which were excluded from all analyses.
Sensitivity analyses revealed that exclusion of these out-
liers did not influence the interpretation of the results.
To illustrate the magnitude of the difference in percen-
tage breast density according to xenoestrogen levels,
separate models included each xenoestrogen serum level
categorized as nondetectable, below the median of
detectable values, and above the median of detectable
values. Adjusted least-squares mean levels of square-root
percentage density were calculated according to these
categorized groups and reverse transformed for display
purposes. Trend tests across categorized groups were
conducted by including the serum-level category as an
ordinal term in the regression models. We hypothesized
that xenoestrogen chemicals may influence breast tissue
more strongly in a low endogenous hormone environ-
ment. Tests for modification of the relation between
xenoestrogens and percentage breast density by serum
estradiol and BMI were conducted by including continu-
ous cross-product interaction terms in the regression
models.
Finally, all analyses were repeated by using the square
root of dense area (rather than percentage density) as
the outcome of interest.
Results
Table 1 summarizes the characteristics of the study sub-
jects. The mean age of participants was 60.6 years (stan-
dard deviation, 4.4 years). About 31% of participants
were overweight, and 37% were obese. In general, the
study population was highly educated (80.7% had
attended at least some college) and reported low smok-
ing rates (60.2% had never smoked).
The distributions of the measured serum phthalates,
parabens, and phenols are described in Table 2. Propyl
paraben and butyl paraben were detected in more than half
of the study samples. Mono-ethyl phthalate, octylphenol,
Table 1 Characteristics of study participants (N = 264),
Wisconsin Breast Density Study, 2008 to 2009
Mean ± SD or n (%)
Age (years) 60.6 ± 4.4
Body mass index (kg/m2)a 28.9 ± 6.6









Vigorous physical activity (hours per week)b 4.2 ± 5.0
College degreec 153 (58.2)
SD, standard deviation. aBody mass index data was missing for two subjects.
bPhysically vigorous activities that cause large increases in heart rate or
breathing, such as sports activities, climbing stairs, heavy gardening, or lifting/
carrying heavy objects. cEducation data were missing for one subject.
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nonylphenol, and BPA were detected in 13% to 41% of
samples. Mono-butyl phthalate and mono-benzyl phthalate
were detected in very few samples (1.9% and 0.4%, respec-
tively) and were not considered in further analyses. Table 3
presents the Spearman correlation coefficients between
each of the xenoestrogens and subject age, BMI, and
serum estradiol. A number of xenoestrogens exhibited
modest correlations with each other, the strongest of
which was between propyl and butyl paraben (r = 0.36).
Moderate correlation was found between nonylphenol and
estradiol (r = 0.20). No statistically significant correlations
were observed between xenoestrogen values and subject
age or BMI.
In the multivariable-adjusted linear regression models,
the square root of percentage density was positively asso-
ciated with mono-ethyl phthalate (b = 0.034; P = 0.01) and
BPA (b = 0.191; P = 0.01). No evidence was noted for an
association between percentage breast density and propyl
paraben, butyl paraben, octylphenol, or nonylphenol serum
levels when treated as continuous variables (all P > 0.10).
Results from the regression models using categorized
serum xenoestrogen levels are displayed in Table 4.
Mean percentage density was 12.6% among women with
nondetectable BPA levels, 13.7% among women with
detectable levels below the median (<0.55 ng/ml), and
17.6% among women with detectable levels above the
median (Ptrend = 0.01). Percentage breast density was
also elevated (18.2%) among women with serum mono-
ethyl phthalate above the median detected level, but the
trend was of borderline statistical significance (Ptrend =
0.07). No evidence was found for a trend in percentage
breast density with increasing categories of propyl para-
ben, butyl paraben, octylphenol, or nonylphenol levels.
We assessed whether the associations of BPA and
mono-ethyl phthalate with percentage breast density
varied according to measures of the endogenous hor-
mone environment, including BMI and serum estradiol.
No evidence was seen for an interaction between mono-
ethyl phthalate and BMI or estradiol. The association
between BPA and percentage breast density varied
according to BMI (Pinteraction = 0.03). BPA levels were
positively associated with percentage density only
among women who were not obese (Figure 1). However,
the association of BPA with percentage breast density
Table 2 Distribution of serum phthalates, parabens, and phenols in study participants (N = 264), Wisconsin Breast
Density Study, 2008 to 2009
Limit of detection No. (%) with detectable levels Median detectable valuea Maximum detected value
Mono-ethyl phthalate (ng/ml) 0.11 37 (14.1) 3.77 55.8
Mono-butyl phthalate (ng/ml) 1.00 5 (1.9) NAb 136
Mono-benzyl phthalate (ng/ml) 0.10 1 (0.4) NAb 0.2
Propyl paraben (ng/ml) 0.07 175 (66.5) 0.46 630.0
Butyl paraben (ng/ml) 0.02 143 (54.2) 0.13 2.26
Octylphenol (ng/ml) 0.25 35 (13.3) 1.78 58.2
Nonylphenol (ng/ml) 0.06 109 (41.3) 16.8 725.0
Bisphenol A (ng/ml) 0.24 69 (26.3) 0.55 8.77
aRefers to the median of serum levels among samples with detectable values (that is, excluding nondetectable samples). bNot available; summary statistics were
not calculated because of insufficient numbers of subjects with detectable levels.
Table 3 Spearman correlation coefficients between serum xenoestrogens and other subject characteristics (N = 264),
Wisconsin Breast Density Study, 2008 to 2009
















































BMI, body mass index.
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did not appear to be modified by serum estradiol level
(Pinteraction = 0.58).
In general, similar results were obtained when evaluat-
ing the relation between each xenoestrogen chemical and
dense breast area (rather than percentage density). Multi-
variable-adjusted regression revealed positive associations
between dense area and mono-ethyl phthalate (Ptrend =
0.03) and BPA (Ptrend = 0.08). Effect modification of the
association between BPA and dense area by body mass
index was not statistically significant (Pinteraction = 0.31),
but a similar pattern was observed in which the elevation
of dense area with high BPA levels was largely restricted
to women who were not obese (data not shown).
Discussion
This study provides the first evidence that mammographic
breast density varies according to circulating serum levels
of xenoestrogens in postmenopausal women. We found
that serum levels of BPA and mono-ethyl phthalate were
associated with elevated percentage breast density indepen-
dent of BMI and other covariates. For both chemicals, per-
centage breast density was elevated by about 5 percentage
points among women with serum levels above the median
detected value compared with women with undetectable
levels. Mammographic breast density is known to be one
of the strongest risk factors for breast cancer [21,22].
Previous studies suggest that a 5-percentage-point differ-
ence in percentage density corresponds to an approxi-
mately 5% to 10% increase in breast cancer risk [33,34].
For comparison, an absolute difference of 5 percentage
points in percentage breast density is similar to the average
increase in percentage density observed after 1 year of
estrogen-plus-progestin postmenopausal hormone use
[24,35], which is a known breast cancer risk factor.
To our knowledge, no previous studies have evaluated
mammographic breast density in relation to biological
measures of phthalate, paraben, or phenol exposures. We
are aware of only one study examining the relation
between these chemicals and breast cancer risk in humans.
A case-control study examined breast cancer risk in rela-
tion to phthalates in urine samples from Mexican women
[20]. Women with urinary mono-ethyl phthalate levels in
the highest tertile were more than twice as likely to have
breast cancer as were women in the lowest tertile (odds
Table 4 The association of serum phthalates, parabens, and phenols with mammographic breast density (N = 264),
Wisconsin Breast Density Study, 2008 to 2009
Mean percentage density (95% confidence interval)a,b
Chemical Nondetected Below mediand Above mediand Ptrend
c
n = 225 n = 19 n = 18
Mono-ethyl phthalate 13.1 (11.9, 14.3) 13.0 (9.1, 17.7) 18.2 (13.4, 23.7) 0.07
n = 88 n = 88 n = 87
Propyl paraben 12.7 (10.9, 14.8) 13.3 (11.4, 15.4) 13.9 (12.0, 16.1) 0.41
n = 121 n = 72 n = 71
Butyl paraben 14.4 (12.7, 16.3) 12.4 (10.4, 14.7) 12.4 (10.4, 14.7) 0.13
n = 228 n = 19 n = 16
Octylphenol 13.5 (12.3, 14.7) 11.3 (7.6, 15.6) 14.5 (9.9, 19.9) 0.93
n = 155 n = 55 n = 54
Nonylphenol 14.1 (12.6, 15.6) 12.1 (9.8, 14.7) 12.5 (10.1, 15.1) 0.21
n = 193 n = 35 n = 34
Bisphenol A 12.6 (11.4, 14.0) 13.7 (10.7, 17.1) 17.6 (14.1, 21.5) 0.01
SE, standard error. aAdjusted for age, body mass index, parity, family history of breast cancer, vigorous physical activity, and smoking. bMean percentage density
displayed is reverse transformed from model of square root density. cPtrend refers to the test for the ordinal variable representing nondetected, below median

























Figure 1 The association between serum BPA and percent
breast density by obesity status, Wisconsin Breast Density
Study, 2008-2009. Percentage breast density shown is reverse
transformed from regression model of square root percentage
density and adjusted for age, parity, family history of breast cancer,
vigorous physical activity, and smoking; error bars indicate 95%
confidence limits. The data include 96 obese women and 166
women who were not obese.
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ratio, 2.2; 95% CI, 1.33 to 3.63). Our finding of elevated
percentage breast density among women with high circu-
lating serum levels of mono-ethyl phthalate is consistent
with this finding.
Humans are generally exposed to phthalates as diesters
in consumer products. The metabolism of these diesters
is rapid, with elimination half-lives generally less than
24 hours [36]. Excretion of phthalate metabolites occurs
primarily via urine [1]. Mono-ethyl phthalate is the pri-
mary metabolite of diethyl phthalate. Products that may
contain diethyl phthalate include perfumes, deodorants,
soaps, shampoos, cosmetics, and lotions [1].
BPA is widely used in plastics and cans for food
packaging, and BPA exposure is considered to occur
predominantly through food [3]. After ingestion, BPA is
metabolized through glucuronidation, with acute-exposure
studies suggesting an elimination half-life in the body of
about 4 to 6 hours [3]. However, a recent NHANES study
suggested that either substantial nonfood sources of expo-
sure exist, or substantial accumulation of BPA occurs in
body compartments with long elimination times [37].
Despite its short half-life in the body, BPA appears to be
present in adipose tissue in its lipophilic unconjugated
forms [38]. Release of free BPA from adipose tissue may
represent a source of continuous exposure for target
organs [6].
The mechanisms by which mono-ethyl phthalate or
BPA exposure could influence mammographic breast
density are unclear. In vitro and in vivo assays indicate
that phthalates and BPA have estrogenic activity [8,9].
The serum concentration of these chemicals in our study
population was about 100 to 1,000 times higher than that
of estradiol; however, the estrogenic potency of mono-
ethyl phthalate and BPA is believed to be 10,000 to 1 mil-
lion times less than that of estradiol. In vitro experiments
and human studies provide inconsistent evidence for
mutagenicity [16,39], and animal studies have revealed
limited evidence for impacts on the mammary gland in
adult animals [1,40]. However, evidence suggests that the
offspring of rats exposed to BPA during pregnancy exhi-
bit altered mammary gland architecture during puberty
and adulthood, including an increased number of hyper-
plastic mammary ducts, increased stromal nuclear den-
sity, and increased terminal end-bud density [41,42].
Additionally, a recent study reported that urinary BPA
levels were associated with upregulated estrogen receptor
and estrogen-related receptor expression among adult
men [43]. Recent studies have also revealed that environ-
mentally relevant doses of BPA can influence adiponectin
production in human adipose tissue, which could influ-
ence insulin sensitivity and tissue inflammation [44].
We explored potential interactions between the xenoes-
trogen exposures and the internal hormone environment.
We had hypothesized that the role of xenoestrogens may
be attenuated in women with higher endogenous hormone
levels. The association between BPA and percentage breast
density was limited to women who were not obese, which
was consistent with our hypothesis, because obese women
have higher endogenous hormone levels [45]. However,
when we directly examined effect modification by endo-
genous estradiol levels, we found no evidence for an inter-
action. The interpretation of these findings is somewhat
unclear, but they suggest that the role of obesity in effect
modification may be independent of a sex hormone path-
way. Notably, endogenous estrogens do not appear to be
strongly associated with mammographic breast density
[27], whereas obesity has a strong inverse association with
mammographic breast density that is independent of hor-
mone levels. The strong predisposition of obese women to
have low mammographic density may limit any potential
effect of BPA within this subgroup. Alternatively, the lack
of effect modification by estradiol may be due to the small
sample size or the limited range of estradiol levels
observed in this sample of postmenopausal women. Given
the limited power and precision for estimating effect mod-
ification, these findings require replication and should be
interpreted with caution. The results do suggest that
future studies should test effect modification by BMI, and
if possible, by endogenous hormones that affect breast
cancer risk, because the role of environmental exposures
may vary across these subgroups.
The primary limitation of our study is the use of a
single serum measurement to assess exposure levels. As
described earlier, the metabolism and excretion of
phthalates, parabens, and phenols is rapid and efficient.
Although the pharmacokinetics of mono-ethyl phthalate
and BPA metabolism are not completely understood, it is
clear that these chemicals have short elimination half-lives.
Thus, serum measurements largely reflect exposures within
the past 24 hours. The correlation of one serum measure-
ment with exposure history is unknown for these che-
micals, and we are unaware of prior studies that have
examined multiple serum measurements of BPA or phtha-
lates in individuals over time. Prior studies have most often
used urine samples to evaluate exposure levels in popula-
tion studies, because phthalate and BPA concentrations are
about 20 to 100 times higher in urine than in blood [39,40].
Some evidence indicates low to moderate correlation
between urinary BPA and phthalate measures taken a
month or more apart, with observed intraclass correlation
coefficients of approximately 0.1 to 0.3 for BPA and 0.3 to
0.5 for mono-ethyl phthalate [46-50]. Misclassification of
subject exposure levels would tend to bias our results
toward a null association and would thus not appear to
explain the observed positive associations. It is also possible,
however, that the associations between circulating levels of
monoethyl phthalate and BPA and percentage breast den-
sity may be due to confounding by an unmeasured factor
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that influences both xenoestrogen metabolism and mam-
mographic breast density.
Despite the limitations with xenoestrogen serum mea-
surements, they were previously shown to demonstrate
associations with polycystic ovarian syndrome, obesity,
and recurrent miscarriage [14,41]. One potential advan-
tage of serum measurements is that they may more
directly assess circulating concentrations that reflect the
biologically relevant exposure of the target organs [6].
Further investigation with more comprehensive expo-
sure measurements and longitudinal study designs will
be necessary to confirm and further examine the asso-
ciations observed in our study. Studies are also needed
in more diverse populations, as our study subjects were
predominantly non-Hispanic whites (97% of our study
subjects), highly educated, limited in age range, and had
a high prevalence of family history of breast cancer.
Although these attributes are consistent with the source
population of women undergoing screening mammogra-
phy in our recruitment centers, future studies would
benefit from inclusion of more-diverse study subjects
with a wider range of exposure levels.
Conclusions
The results of this study indicate that serum levels of
mono-ethyl phthalate and BPA are cross-sectionally
associated with elevated mammographic breast density
in postmenopausal women. Given the widespread expo-
sure of the population to these chemicals and the strong
association between mammographic breast density and
breast cancer risk, further research is warranted to
examine the potential role of these chemicals in breast
carcinogenesis in humans.
For mono-ethyl phthalate, the consistency between
our findings and those of a previous case-control study
of breast cancer risk are particularly striking. The results
observed here must be confirmed in larger study popu-
lations. Future studies evaluating these exposures in
relation to mammographic breast density or breast can-
cer risk should seek to use longitudinal study designs,
multiple exposure assessments, and diverse study
populations.
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